Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.62 |
| ▸ | CA1 | P00915 | 14/20 | 0.62 |
| ▸ | CA9 | Q16790 | 13/20 | 0.62 |
| ▸ | CA12 | O43570 | 11/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 5/20 | 0.55 |
| ▸ | CA4 | P22748 | 3/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6201900 | 0.84 | RAB9A (0.59) | CA2CA1 | |
| SCHEMBL6168486 | 0.84 | CA1 (0.62) | CA2CA1CA9CA12CA7 | |
| SCHEMBL4772305 | 0.84 | PTGS2 (0.53) | — | |
| SCHEMBL6970870 | 0.84 | PTGS2 (0.53) | — | |
| SCHEMBL6026667 | 0.83 | CA1 (0.61) | CA2CA1CA9CA12MAOA | |
| SCHEMBL7220270 | 0.82 | CA2 (0.56) | CA2CA1CA9CA12CA7 | |
| SCHEMBL6168504 | 0.80 | CA2 (0.65) | CA2CA1CA9CA12CA7 | |
| SCHEMBL21180477 | 0.80 | RAB9A (0.50) | — | |
| SCHEMBL5724883 | 0.78 | RAB9A (0.68) | CA2 | |
| SCHEMBL7167952 | 0.78 | SRD5A2 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6998415-B2 | Pyrazolyl derivatives; antiinflammatory agents for inflammation; antiallergens for asthma | PHARMACIA CORPORATION (US) | 2006-02-14 | — | — | US | disclosed |
| US-20040147565-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G.D. SEARLE & CO. | 2004-07-29 | — | — | US | disclosed |
| US-6677364-B2 | ANTI-INFLAMMATORY, ANTIPYRETIC, ANALGESIC COMPOSITIONS | G.D. SEARLE & CO. | 2004-01-13 | — | — | US | disclosed |
| US-6670365-B1 | Treatment of inflamation and/or cyclooxygenase-mediated diseases, reduced ulcerogenic effects; 2-phenyl-3-(4-methylsulfonylphenyl)imidazo(1,2-a)pyrimidine | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2003-12-30 | — | — | US | disclosed |
| EP-0828736-B1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | SEARLE & CO (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-1104762-B1 | SUBSTITUTED IMIDAZO[1,2A]AZINES AS SELECTIVE INHIBITORS OF COX-2 | S A L V A T LAB SA (ES) | 2002-09-18 | — | — | EP | disclosed |
| EP-0995747-B1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | SEARLE & CO (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020086886-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G.D. SEARLE & CO. | 2002-07-04 | — | — | US | disclosed |
| EP-1104762-A1 | SUBSTITUTED IMIDAZO 1,2A]AZINES AS SELECTIVE INHIBOTORS OF COX-2 | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2001-06-06 | — | — | EP | disclosed |
| EP-0995747-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G.D. SEARLE & CO. (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0825989-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-03-04 | — | — | EP | disclosed |
| WO-1996036617-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147565-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX12, ALOX15 | CA2 2824/4885CA1 4399/4885CA9 4224/4885 |
| US-20020086886-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, PTGES2, PTGS2 | CA2 2286/4885CA1 3741/4885CA9 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.